{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:59:02Z","timestamp":1791197942819,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12185-026-04238-7","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:28:23Z","timestamp":1781090903000},"page":"568-579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic impact of WT1 dynamics in peripheral blood before and after allogeneic HSCT in patients with AML and MDS"],"prefix":"10.1007","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2929-3980","authenticated-orcid":false,"given":"Tomoyoshi","family":"Wakayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Imoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Ukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Kurahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"22","key":"4238_CR1","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2009.813","volume":"301","author":"J Koreth","year":"2009","unstructured":"Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349\u201361.","journal-title":"JAMA"},{"issue":"7","key":"4238_CR2","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1038\/leu.2015.37","volume":"29","author":"M Robin","year":"2015","unstructured":"Robin M, Porcher R, Ad\u00e8s L, Raffoux E, Michallet M, Fran\u00e7ois S, et al. HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM. Leukemia. 2015;29(7):1496\u2013501.","journal-title":"Leukemia"},{"issue":"3","key":"4238_CR3","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s12185-022-03416-7","volume":"116","author":"F Kreidieh","year":"2022","unstructured":"Kreidieh F, Abou Dalle I, Moukalled N, El-Cheikh J, Brissot E, Mohty M, et al. Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment. Int J Hematol. 2022;116(3):330\u201340.","journal-title":"Int J Hematol"},{"issue":"26","key":"4238_CR4","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138(26):2753\u201367.","journal-title":"Blood"},{"issue":"12","key":"4238_CR5","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, B\u00e9n\u00e9 MC, Buccisano F, Cloos J, et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275\u201391.","journal-title":"Blood"},{"key":"4238_CR6","doi-asserted-by":"crossref","unstructured":"Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, et al; French AML Intergroup. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121(12):2213\u201323.","DOI":"10.1182\/blood-2012-10-462879"},{"key":"4238_CR7","doi-asserted-by":"crossref","unstructured":"Ariyaratana, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med. 2007;9(14):1\u201317.","DOI":"10.1017\/S1462399407000336"},{"issue":"5","key":"4238_CR8","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/j.1365-2141.2004.04952.x","volume":"125","author":"M \u00d8stergaard","year":"2004","unstructured":"\u00d8stergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. Br J Haematol. 2004;125(5):590\u2013600.","journal-title":"Br J Haematol"},{"issue":"1","key":"4238_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12185-015-1882-1","volume":"103","author":"K Kitamura","year":"2016","unstructured":"Kitamura K, Nishiyama T, Ishiyama K, Miyawaki S, Miyazaki K, Suzuki K, et al. Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood. Int J Hematol. 2016;103(1):53\u201362.","journal-title":"Int J Hematol"},{"issue":"4","key":"4238_CR10","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00277-020-03910-0","volume":"99","author":"E Bussaglia","year":"2020","unstructured":"Bussaglia E, Pratcorona M, Carricondo M, Sansegundo L, Rubio MA, Monter A, et al. Application of a digital PCR method for WT1 to myeloid neoplasms in CR and deep ELN WT1 molecular response (< 10 copies). Ann Hematol. 2020;99(4):765\u201372.","journal-title":"Ann Hematol"},{"issue":"11","key":"4238_CR11","doi-asserted-by":"publisher","first-page":"1088.e1","DOI":"10.1016\/j.jtct.2024.08.008","volume":"30","author":"S Nakako","year":"2024","unstructured":"Nakako S, Okamura H, Yokota I, Umemoto Y, Horiuchi M, Sakatoku K, et al. Dynamic relapse prediction by peripheral blood WT1mRNA after allogeneic hematopoietic cell transplantation for myeloid neoplasms. Transplant Cell Ther. 2024;30(11):1088.e1-1088.e12.","journal-title":"Transplant Cell Ther"},{"issue":"17","key":"4238_CR12","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.3390\/jcm13175145","volume":"13","author":"S Namdaro\u011flu","year":"2024","unstructured":"Namdaro\u011flu S, Ba\u015fc\u0131 S, Aslan Cand\u0131r B, Yaman S, Yi\u011feno\u011flu TN, Bahsi T, et al. Role of WT1 in measurable residual disease follow-up in the post allogeneic stem cell transplant setting. J Clin Med. 2024;13(17):5145.","journal-title":"J Clin Med"},{"issue":"10","key":"4238_CR13","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.bbmt.2017.06.007","volume":"23","author":"K Ino","year":"2017","unstructured":"Ino K, Fuji S, Tajima K, Tanaka T, Okinaka K, Inamoto Y, et al. Clinical utility of Wilms\u2019 tumor 1 monitoring in patients with myeloid malignancy and prior allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(10):1780\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"4238_CR14","doi-asserted-by":"publisher","first-page":"2285801","DOI":"10.1080\/15384047.2023.2285801","volume":"24","author":"T Yu","year":"2023","unstructured":"Yu T, Zhan Q, Yan X, Luo X, Wang X, Tang X, et al. Clinical significance of WT1 in the evaluation of therapeutic effect and prognosis of non-M3 acute myeloid leukemia. Cancer Biol Ther. 2023;24(1):2285801.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"4238_CR15","doi-asserted-by":"publisher","first-page":"168.e1","DOI":"10.1016\/j.jtct.2024.12.007","volume":"31","author":"T Tsushima","year":"2025","unstructured":"Tsushima T, Kimeda C, Yoda N, Matsuo K, Tanaka K, Hatanaka Y, et al. Clinical outcomes of early WT1 mRNA reduction after remission induction in newly diagnosed acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2025;31(3):168.e1-168.e12.","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"4238_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/ejh.13664","volume":"107","author":"C Rautenberg","year":"2021","unstructured":"Rautenberg C, Lauseker M, Kaivers J, J\u00e4ger P, Fischermanns C, Pechtel S, et al. Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS. Eur J Haematol. 2021;107(2):283\u201392.","journal-title":"Eur J Haematol"},{"issue":"12","key":"4238_CR17","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"3","key":"4238_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"4238_CR19","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664\u201371.","journal-title":"Blood"},{"issue":"3","key":"4238_CR20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jgo.2014.04.003","volume":"5","author":"JW Keller","year":"2014","unstructured":"Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, et al. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014;5(3):238\u201344.","journal-title":"J Geriatr Oncol"},{"issue":"3","key":"4238_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s12185-024-03795-z","volume":"120","author":"S Arai","year":"2024","unstructured":"Arai S, Tachibana T, Izumi A, Takeda T, Tamai Y, Sato S, et al. WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Int J Hematol. 2024;120(3):337\u201346.","journal-title":"Int J Hematol"},{"issue":"5","key":"4238_CR22","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1182\/blood-2002-06-1831","volume":"101","author":"H Ogawa","year":"2003","unstructured":"Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood. 2003;101(5):1698\u2013704.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04238-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04238-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04238-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:59:22Z","timestamp":1791194362000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04238-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4238"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04238-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}